Bressler NM, et al. - In this study, the outcomes of diabetic macular edema (DME) persisting at least 24 weeks post-randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab were assessed. Persistent DME was more likely with bevacizumab as compared to the aflibercept or ranibizumab. Among eyes with persistent DME, eyes treated with bevacizumab were more likely to have chronic persistent DME than eyes treated with aflibercept. Regardless of anti–vascular endothelial growth factor agent given or persistence of DME through 2 years, the findings suggest meaningful gains in vision with little risk of vision loss. Exercising caution was recommended when considering switching therapies for persistent DME following 3 or more injections; improvements could be owing to continued treatment rather than switching therapies.